Non-small cell lung cancer (NSCLC)

Non-small cell lung cancer
#AstraZeneca #FDA #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Combination therapy reduced risk of lung cancer progression by 38%

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon… Read More

#News #Regulatory

Non-small cell lung cancer
#Apollomics #Avistone Biotechnology #China #Non-small cell lung cancer (NSCLC) #Oncology

c-Met inhibitor approved in China for lung cancer

The Chinese National Medical Products Administration (NMPA) has granted conditional approval to Apollomics’ partner Avistone Biotechnology to commercialise vebreltinib (APL-101) in China for MET exon 14 skipping non-small cell lung cancer (NSCLC). “The NMPA approval of vebreltinib is an important milestone toward providing a new treatment… Read More

#News #Regulatory

Non-small cell lung cancer
#Lung cancer #MHRA #Mirati Therapeutics #Non-small cell lung cancer (NSCLC) #Oncology #UK

MHRA approves drug for lung cancer with limited therapy options

The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Krazati (adagrasib) to treat patients whose disease is… Read More

#News #Regulatory

Lung cancer
#FDA #Non-small cell lung cancer (NSCLC) #Oncology #Orphan drugs #Pfizer

Orphan designated precision drug approved in US for NSCLC

The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion… Read More

#News #Regulatory

Non-small cell lung cancer
#Gene therapy #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Non-viral gene therapy shows early efficacy in lung cancer

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC). The data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. Developed by… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Cancer research #FDA #Mythic Therapeutics #Non-small cell lung cancer (NSCLC)

FDA fast-tracks ADC for non-small cell lung cancer 

The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for… Read More

#News